Status:
COMPLETED
Evaluation of Oxiris Membrane as a Treatment for Ischemia-reperfusion Syndrome in Cardiogenic Shock Treated With Extracorporeal Life Support (ECMO/ECLS): A Randomized Pilot Study ECMORIX
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Cardiogenic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The Oxiris membrane is an AN-69 membrane whose surface is treated with polyethyleneimine (PEI) grafted with heparin. This property allows the removal of lipopolysaccharide and cytokines from the blood...
Eligibility Criteria
Inclusion
- Trusted person or relative who has given oral consent or emergency consent
- Person of legal age
- Patient receiving ECLS for refractory cardiogenic shock requiring continuous renal replacement therapy
- Included within 12 hours of ECLS initiation
Exclusion
- Person not affiliated to national health insurance
- Person under legal protection (curatorship, guardianship)
- Person under court order
- Pregnant or breastfeeding woman
- Minor
- Severe hemorrhage under ECLS
Key Trial Info
Start Date :
May 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 10 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04886180
Start Date
May 18 2021
End Date
March 10 2023
Last Update
February 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourgogne
Dijon, France